The UCLA Vine Street Clinic served as one of the study sites for the HPTN 083 trial, a study that sought to compare the efficacy of cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) for HIV prevention. Data obtained from this and other studies helped inform the U.S. Food and Drug Administration (FDA)’s approval of long-acting cabotegravir (CAB-LA) injections for the prevention of HIV. “Results of this NIAD/NIH sponsored and co-funded study showed that CAB-LA injected once every eight weeks was superior to daily oral TDF/FTC for HIV prevention among cisgender men and transgender women who have sex with men (HPTN 083) and cisgender women (HPTN 084). Both studies also demonstrated that CAB-LA was well-tolerated, offering a new and important pre-exposure prophylaxis (PrEP) option for individuals at risk for HIV infection.” The protocol chair for HPTN 083 is Dr. Raphael Landovitz, long-time CBAM colleague and Co-Director of the Center for HIV Identification, Prevention and Treatment Services.
To read the full press release and learn more about the HPTN 083 study, click here | HPTN 083